RICHMOND, Calif., March  19, 2026  (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year

SGMO

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

Sangamo Therapeutics to Release Q4 and FY 2025 Results on March 30

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>RICHMOND, Calif., March  19, 2026  (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Sangamo Therapeutics is set to announce its financial results for Q4 and FY 2025 on March 30, 2026. This earnings report and accompanying conference call may provide significant insights into the company’s operational performance and pipeline developments, which could impact investor sentiment and stock price.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>SGMO will release Q4 and FY 2025 results on March 30.</li><li>A conference call is scheduled to provide business updates.</li><li>Sangamo focuses on genomic medicine for severe neurological diseases.</li><li>The company utilizes zinc finger technology for therapeutic options.</li><li>Current pipeline includes partnered programs and investment opportunities.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Sangamo Therapeutics (SGMO)</strong>: Key financial results due March 30 may affect stock performance.</li></ul>
  </section>

  <section data-block="category">
    <h3>Earnings</h3>
    <p>This event fits under &#039;Earnings&#039; as it involves scheduled financial disclosures that are likely to impact stock valuation and investor sentiment. The earnings report will address both financial metrics and updates on pipeline progress, essential for informing investor decisions.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Upcoming earnings report could reveal pipeline progress and financial health.</li><li>Successful results might lead to increased investment interest in SGMO.</li><li>Any partnerships or new partnerships announced could enhance growth prospects.</li><li>CEO&#039;s comments on new therapies may impact investor outlook strongly.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Q4 and FY 2025 results will be released on March 30, 2026.</li><li>Sangamo focuses on genomic medicine, particularly for neurological diseases.</li><li>Conference call will provide updates on financial results.</li><li>The pipeline includes partnered programs for potential revenue streams.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Invest in SGMO ahead of results for potential upward momentum into Q2 2026.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">RICHMOND, Calif., March  19, 2026  (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/SGMO">SGMO</a>), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2025 financial results after the market closes on Monday, March 30, 2026.</p>  <p align="justify">The company will hold a conference call at 4:30 p.m. Eastern on Monday, March 30, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates.</p>  <p align="justify">Participants should register for, and access, the call using <a href="https://www.globenewswire.com/Tracker?data=lvvUvRqrpZUMznp_xZf4NYI94QpKv0g7D--DNpl4lyjPo9VhzQSfOxCVQGkJxZsHZHWG7SkAvwDCg1B2arzeBUbrtXlhGr6WyB6CoaVYx9iQK4IgFuZNjkwDXr8XAJsoZYBYlMbaMkzCWklIl76n-L2oEZ_aY7Qd-p_vaulsNuA=" rel="nofollow" target="_blank">this link</a>. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under <a href="https://www.globenewswire.com/Tracker?data=kKK2b1nriSUs5ftvkXqbFy7xbx8JF0g4Ufhc6gLmqepH1GDVvgoz9Rh2LKDCZalnBgRSn-BqSBDwgi4XbyjeWCaayJZHFk_cIHnIks_uiMQ_9atRXZhEoEaqPoNT6i3Q" rel="nofollow" target="_blank">Events</a>.</p>  <p align="justify">A replay will be available following the conference call, accessible under <a href="https://www.globenewswire.com/Tracker?data=kKK2b1nriSUs5ftvkXqbF5nRN-euv9PSRuli4GvMcKCklwEWWJnb6hXSQ4DEV4yB2O50mnNBAWqQbWxvVwdODsMlLHMG0B-fbB66g-MYJeXEfc0IV49Mc1iVxBNrRePk" rel="nofollow" target="_blank">Events</a>.</p>  <p align="justify"><strong>About Sangamo Therapeutics</strong><br></br>Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo's pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit <a href="https://www.globenewswire.com/Tracker?data=lSiXC7QmB9kVJkko5JqIIio5MJkKD5VAo3fW5SrTRCJ6_jop6E9K22FrRcPPStRBmIp3zCjU5cvL9Nw6SsE7ZAqrZbg6HA7uw1YVGfYbs5rvfVLMN-KtKnZnge2ndY0NwWTflZotkA6YUtkLaMUBLnYzlhsqDHvzgafnMH63OrTE2ieF934_Y4LUOL8JH1r047pcmhLhN-gwmTqCNLJ6qeUSMy7pzWiSC8iPTEw7-RplDjBBcdSUT4B0E1aVQCpX1puJkrRWEUqGAdZIkw_OprUwstQhyBDjmbCHzPB-6uaC5m6oVSvEh2aCPAWCyvjXi_rWd37IpbXHgEieK7dMgw==" rel="nofollow" target="_blank">www.sangamo.com</a> and connect with us on <a href="https://www.globenewswire.com/Tracker?data=ZiUybapCY75SYE1L0dVk9VoGFo_aBM9dD4_7id_oIpfyCjjWt9ThPmEkIPajb1Ti_MqQtnpO8_Yrn_6rcE_nUTisk05n_FZ7fzTC5xHfM3zijRJn6Q2qxJl4x5CUWy2b" rel="nofollow" target="_blank">LinkedIn</a>.</p>  <p align="justify"><strong>Investor Relations and Media Inquiries</strong><br></br>Louise Wilkie<br></br><a href="https://www.globenewswire.com/Tracker?data=1C10-3Dk2w7gB_y5ygr3DpX8C60Va98O0_5AqLVE9mgc5v6jBK1eqjsUnyKakU0bLoGYPZkAq1CnT1hkQaGZrQ==" rel="nofollow" target="_blank">ir@sangamo.com</a> <br></br><a href="https://www.globenewswire.com/Tracker?data=ymTjNdZ7LRdg4sbBnNvb_lyNlKmmFLeDBA8J_KoG2PAiGOUtOgP8j93JcASH6ZhRhvIXBZeU8LnAYDk-tJ9CQu-hghou9IlYSLHB0Gs0Snw=" rel="nofollow" target="_blank">media@sangamo.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY3NDkzMyM3NDkzNDQ4IzIwMDQxNjM="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ODAyZjg4NmItMjVkNC00ZGNkLWJkZjEtMjBhNGMyMDQ0NWUwLTEwMTU3MzYtMjAyNi0wMy0xOS1lbg==/tiny/Sangamo-Therapeutics-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/e3084490-aff3-4c15-8036-d94123563fd0"><img src="https://ml.globenewswire.com/media/e3084490-aff3-4c15-8036-d94123563fd0/small/sangamo-logotm-11-11zon-png.png" border="0" width="150" height="37" alt="Primary Logo"></img></a></p>

Sangamo Therapeutics is set to announce its financial results for Q4 and FY 2025 on March 30, 2026. This earnings report and accompanying conference call may provide significant insights into the company’s operational performance and pipeline developments, which could impact investor sentiment and stock price.

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Earnings

Related News